Sistema osteoprotegerin (OPG) -ligand retseptora-aktivatora yadernogo faktora kappa-V (RANKL) pri diabeticheskoy neyroosteoartropatii i obliteriruyushchem ateroskleroze arteriy nizhnikh konechnostey
https://doi.org/10.14341/2072-0351-5792
Abstract
About the Authors
Марианна Viktorovna YaroslavtsevaIrina Nikolaevna Ul'yanova
Gagik Radikovich Galstyan
References
1. Дедов И.И., Шестакова М.В. (2003) Сахарный диабет. Руководство для врачей. М.: Универсум Паблишинг - с.263
2. Дедов И.И., Чазова Т.Е., Сунцов Ю.И. (2003) Эпидемиология сахарного диабета. Пособие для врачей. М. - с.56
3. Jeffcoate W. (2004) Vascular calcification and osteolysis in diabetic neuropathy - is RANK-L the missing link? Diabetologia . 47:1488-1492
4. Miazgovski T., Andrysiak-Mamos E., Pynka S., Gulinska M., Czekalski S. (1997) The evaluation of bone mineral density and selected markers of bone turnover in patients with insulin-dependent diabetes mellitus. Przegl Lek; 54 (7-8): 533-539.
5. Miazgovski T., Czekalski S. (1998) A 2-year follow-up study on bone mineral density and markers of bone turnover in patients with long-standing insulin-dependent diabetes mellitus. Osteoporos Int. ; 8 (5):399-403.
6. Selby P.L., Jude E.B., et al. (2000) Bone turnover markers in acute Charcot neuroarthropathy. Diabetologia. Sept; 44: A 275
7. Gough A., Abraha H., Li F., Purewall T.S., Foster A.V., Watkins P.J., Moniz C., Edmonds M.E. (1997) Measurement of markers of osteoclast and osteoblast activity in Patients with acute and chronic diabetic Charcot neuroarthropathy. Diabet.Med. July; 14(7):527-531.
8. Дедов И.И., Анциферов М.Б., Галстян Г.Р., Токмакова А.Ю. (1998) Синдром диабетической стопы. М.: Универсум Паблишинг, - с.143
9. Shoppet M., Al-Fakhri N., Franke F., Katz N., Barth P., Maisch B., Preissner K., Hofbauer L. (2004) Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappa B ligand in Monckebergs sclerosis and atherosclerosis. The Journal of Clinical Endocrinology&Metabolism, Vol.89, № 8, 4104-4112.
10. Abedin M., Tintut Y., Demer L. (2004) Vascular calcification: mechanisms and clinical ramifications. Aterosclerosis, thrombosis, and vascular biology; 24; 1164-1170.
11. Hofbauer L., Shoppet M. (2001) Osteoprotegerin: a link between osteoporosis and arterial calcification? The Lancet. Vol.358.
12. Simmonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Dave E., Bucay N., Renshaw-Gregg L., Hughes T.M., Hill D., Pattison W., Campbell P., Boyle W.J. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. V.89: 309-319.
13. Tsuda E., Goto M., Mochizuki S. et al. (1997) Isolation of a novel cytokine from human fibroblasts that specifically inhibites the osteoclastogenesis. Biochem. Biophys. Res. Comm. V.234 P. 137-142
14. Tan K.B., Harrop J., Reddy M. Et al. (1997) Characterization of a novel TNF-like ligand and recently described TNF ligand receptor superfamily genes and their constutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene. V.204. P.35-46.
15. Шварц Г.Я. (2003) Молекулярно-биологические основы создания новых лекарственных средств для лечения остеопороза: 1. Остеопротегерин, ЛОПГ (RANKL) и RANK: физиологический механизм(ы) регуляции костной резорбции. Обзор литературы. Остеопороз и остеопатии №2. - с.21-22
16. Khosla S. (2001) Minireview: the OPG/RANKL/RANK System. Endocrinology 142 (12): 5050-5055
17. Беневоленская Л.И. (2003) Руководство по остеопорозу. М.: БИНОМ. Лаборатория знаний. - с.82
18. Yasuda H., Shima N., Nakagawa N., Mochizucki S.I., Yano K., Fujise N., Sato Y., Goto M., Yamaguchi K., Kuriyama M., Kanno T., Murakami A., Tsuda E., Morinaga T., Higashio K. (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 39:1329-1337.
19. Bucay N., Sarosi I., Dunstan C,R., Morony S., Tarpley J., Capparelli C., Scully S., Tan H.L., Xu W., Lacey D.L., Boyle W.L., Simonet W.S. (1998) Osteoprotegerin deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260-1268.
20. Anderson M.A., Maraskovsky E., Billingsley W.L., Dougall W.S., Tometsko M.E., Roux E.R., Teepe M.C., DuBose R.F., Cosman D., Galibert L. (1997) A homologue of the TNF receptor and its ligand enhance Tcell growth and dendritic-cell function. Nature 390:175-179.
21. Fuller K., Wong B., Fox S., Choi Y., Chambers T.J. (1998) TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J. Exp Med 188:997-10001
22. Bekker P.J., Holloway D., Nalanishi A., et.al. (1999) Osteoprotegerin (OPG) has potent and sustained anti-resorptive activity in postmenopausal women. J. Bone Mineral Reseach; 14 (Suppl.1):S180.
23. Hofbauer L.C., Shui C., Riggs B.L., et al. (2001) Effects of immunosuppressants on receptor activator of NF-kB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cell. Biochem Biophys Res Commun ; 280:334-39.
24. Malyankar U.M., Scatena M., Suchland K.L., Yun T.J., Clarc E.A., Giachechelli C.M. (2000) Osteopronegerin is an -induced, NF- Bdependent survival factor for endothelial cells. J. Biol.Chem; 275: 20959-62.
25. Min H., Morony S., Sarosi I., et. al. (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J. Exp Med; 192: 463-74.
26. Browner W.S., Lui L.Y., Cummings S.R. (2001) Associations of serum osteoprotegerin levels wits diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab; 86: 631-37.
27. Schoppet M., Sattler ANM, Schaefer J.R., Herzum M., Maisch B., Hofbauer L.C. (2003) Increased osteoprotegerin serum levels in men with coronary artery disease. J. Clin Endocrinol. Metabol., 88: 1024- 1028.
28. Yano K., Tsuda E., Washida N. et al. (1999) Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J. Bone Miner. Res.; 14:518-27.
29. Glass C., Witztum J. (2001) Atherosclerosis: The road ahead. Cell; 104:503-516.
30. Parchami F., Morrow A., Balucan J., Leitinger N., Watson A., Tintut Y., Berliner J., Demer L. (1997) Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcifications in osteoporotic patients. Aterosclerosis, thrombosis, and vascular biology; 17; 680-687.
31. Kon T., Cho T.J., Aizawa T. et al. (2001) Expression of osteoprotegerin, receptor activator of NF-kappa B ligand (osteoprotegerin-ligand) and related proinflammatory cytokines during fracture healing. J. Bone Miner. Res ; 16:1004-1014.
Review
For citations:
Yaroslavtseva М.V., Ul'yanova I.N., Galstyan G.R. Sistema osteoprotegerin (OPG) -ligand retseptora-aktivatora yadernogo faktora kappa-V (RANKL) pri diabeticheskoy neyroosteoartropatii i obliteriruyushchem ateroskleroze arteriy nizhnikh konechnostey. Diabetes mellitus. 2007;10(2):24-27. https://doi.org/10.14341/2072-0351-5792
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
